Cellectar Biosciences Inc (CLRB)

Trade CLRB now with
7/18/2018 8:05:55 AM Cellectar Biosciences Announces Positive Interim Results From Phase 2 Clinical Trial For CLR 131
7/13/2018 4:08:52 PM Cellectar Announces 1-for-10 Reverse Stock Split
7/9/2018 8:05:52 AM Cellectar’s CLR 131 Receives FDA Orphan Drug Designation For Treatment Of Ewing’s Sarcoma
6/6/2018 8:05:06 AM FDA Grants Rare Pediatric Disease Designation To Cellectar Biosciences’ CLR 131 For Rhabdomyosarcoma
5/2/2018 8:06:49 AM Cellectar Biosciences Gets Rare Pediatric Disease Designation For CLR 131 To Treat Neuroblastoma
4/17/2018 8:08:58 AM Cellectar Presents Preclinical Data Demonstrating Efficacy Of Fractionated Injections Of CLR 131 In Multiple Myeloma
4/4/2018 8:06:07 AM Cellectar Biosciences Appoints Brian Posner As CFO
3/19/2018 8:07:12 AM Cellectar Biosciences Grants Orphan Drug Designation For CLR 131 To Treat Neuroblastoma
3/6/2018 8:13:04 AM Cellectar Biosciences : Phase 1 Data Shows CLR 124 Uptake In Brain Tumors Accepted For Oral Presentation
2/7/2018 8:18:36 AM Cellectar Secures USPTO Notice Of Allowance For Patent Covering Use Of CLR 131 In Multiple Myeloma
1/29/2018 8:06:15 AM Cellectar Begins DLBCL Cohort In Phase 2 Trial Of CLR 131 In Refractory B-Cell Hematologic Cancers